Intelligence Feed event · Macro · 2026-10-01

    Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial

    Question

    Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial

    Direct answer

    Boehringer Ingelheim and development partner Zealand Pharma published top-line data from the 76-week SYNCHRONIZE-2 Phase III study evaluating survodutide in patients with both obesity and type 2 diabetes. The treatment arm achieved up to 13.1% mean weight loss compared to 3.1% in placebo recipients, while generating significant concurrent glycemic improvements to support upcoming global regulatory dossiers.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-achieves-13-1-weight-loss-in-phase-iii-diabetes-and-obesity-trial-5a5f23

    MACRO
    Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial
    Boehringer Ingelheim and development partner Zealand Pharma published top-line data from the 76-week SYNCHRONIZE-2 Phase III study evaluating survodutide in patients with both obesity and type 2 diabetes. The treatment arm achieved up to 13.1% mean weight loss compared to 3.1% in placebo recipients, while generating significant concurrent glycemic improvements to support upcoming global regulatory dossiers.
    ZLDPY
    Impact
    77
    OCT 1
    SIG
    93%
    ZLDPY
    Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial
    Boehringer Ingelheim and development partner Zealand Pharma published top-line data from the 76-week SYNCHRONIZE-2 Phase III study evaluating survodutide in patients with both obesity and type 2 diabetes. The treatment arm achieved up to 13.1% mean weight loss compared to 3.1% in placebo recipients, while generating significant concurrent glycemic improvements to support upcoming global regulatory dossiers.
    → Positive Phase III efficacy in comorbid diabetes/obesity positions survodutide as a dual glucagon/GLP-1 asset, shifting expected royalty revenues for licensor ZLDPY.
    Impact
    Boehringer Ingelheim and development partner Zealand Pharma published top-line data from the 76-week SYNCHRONIZE-2 Phase III study evaluating survodutide in patients with both obesity and type 2 diabetes. The treatment arm achieved up to 13.1% mean weight loss compared to 3.1% in placebo recipients, while generating significant concurrent glycemic improvements to support upcoming global regulatory dossiers.
    Affected
    ZLDPY
    Transmission
    Positive Phase III efficacy in comorbid diabetes/obesity positions survodutide as a dual glucagon/GLP-1 asset, shifting expected royalty revenues for licensor ZLDPY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYmilestone and future commercial royalty repricing on Phase III successUp1-5dZealand Pharma co-developed and licenses survodutide to Boehringer Ingelheim.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month